• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特发性肺纤维化合并肺气肿的临床特征。

Clinical characteristics of combined pulmonary fibrosis and emphysema.

机构信息

First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.

出版信息

Respirology. 2010 Feb;15(2):265-71. doi: 10.1111/j.1440-1843.2009.01676.x. Epub 2009 Dec 27.

DOI:10.1111/j.1440-1843.2009.01676.x
PMID:20051048
Abstract

UNLABELLED

This study describes the clinical characteristics of patients with CPFE and compares these with patients with COPD. It should therefore be noteworthy that the prevalence of lung cancer might be high in CPFE patients.

BACKGROUND AND OBJECTIVE

Patients with combined pulmonary fibrosis and emphysema (CPFE) are sometimes seen, and we speculate that these patients have some different clinical characteristics from COPD patients. This study clarifies the clinical characteristics of CPFE patients.

METHODS

This was a retrospective study of 47 stable patients with concurrent emphysema and diffuse parenchymal lung disease with fibrosis, based on the findings of chest CT (CPFE patients). The clinical characteristics of CPFE patients were compared with those of emphysema-dominant COPD patients without parenchymal lung disease (COPD patients).

RESULTS

Forty-six of the 47 CPFE patients were male. Paraseptal emphysema was particularly common in the CPFE group. Honeycombing, ground-glass opacities and reticular opacities were present in 75.6%, 62.2% and 84.4% of CPFE patients, respectively. Twenty-two of the 47 CPFE patients (46.8%) had lung cancer. Pulmonary function tests showed that the CPFE group had milder airflow limitation and lower diffusing capacity than the COPD group. Desaturation during 6-min walking test in CPFE patients tended to be more severe than in COPD patients, if the level of FEV1 or 6MWD was equal.

CONCLUSIONS

CPFE patients had some different clinical characteristics in comparison with COPD patients and may also have a high prevalence of lung cancer.

摘要

目的

本研究描述了 CPFE 患者的临床特征,并将其与 COPD 患者进行了比较。因此,CPFE 患者的肺癌患病率可能较高应该值得注意。

背景和目的

有时会见到合并肺纤维化和肺气肿的 CPFE 患者,我们推测这些患者与 COPD 患者具有一些不同的临床特征。本研究旨在阐明 CPFE 患者的临床特征。

方法

这是一项回顾性研究,纳入了 47 例胸部 CT 显示同时存在肺气肿和弥漫性实质肺疾病伴纤维化的稳定患者(CPFE 患者)。比较了 CPFE 患者的临床特征与无实质肺疾病的肺气肿为主的 COPD 患者(COPD 患者)的临床特征。

结果

47 例 CPFE 患者中,46 例为男性。间隔旁肺气肿在 CPFE 组中尤为常见。CPFE 患者中分别有 75.6%、62.2%和 84.4%存在蜂窝肺、磨玻璃影和网状影。47 例 CPFE 患者中有 22 例(46.8%)患有肺癌。肺功能检查显示 CPFE 组的气流受限程度比 COPD 组轻,弥散能力比 COPD 组低。如果 FEV1 或 6MWD 水平相等,CPFE 患者在 6 分钟步行试验中的低氧血症程度比 COPD 患者更严重。

结论

CPFE 患者与 COPD 患者相比具有一些不同的临床特征,并且肺癌的患病率也可能较高。

相似文献

1
Clinical characteristics of combined pulmonary fibrosis and emphysema.特发性肺纤维化合并肺气肿的临床特征。
Respirology. 2010 Feb;15(2):265-71. doi: 10.1111/j.1440-1843.2009.01676.x. Epub 2009 Dec 27.
2
[Chronic obstructive pulmonary disorder (COPD) patients with the syndrome of combined pulmonary fibrosis and emphysema, compared to patients with emphysema alone].[与单纯肺气肿患者相比,合并肺纤维化和肺气肿综合征的慢性阻塞性肺疾病(COPD)患者]
Harefuah. 2013 May;152(5):294-8, 308, 307.
3
Pulmonary function impairment in patients with combined pulmonary fibrosis and emphysema with and without airflow obstruction.合并肺纤维化和肺气肿且伴有或不伴有气流阻塞患者的肺功能损害
Int J Chron Obstruct Pulmon Dis. 2014 Jul 29;9:805-11. doi: 10.2147/COPD.S65621. eCollection 2014.
4
Relationship between quantitative CT metrics and pulmonary function in combined pulmonary fibrosis and emphysema.定量 CT 指标与合并性肺纤维化和肺气肿患者肺功能的关系。
Lung. 2013 Dec;191(6):585-91. doi: 10.1007/s00408-013-9513-1. Epub 2013 Oct 2.
5
Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema.合并性肺纤维化和肺气肿患者的 COPD 急性加重与 IPF 。
Respir Res. 2020 Jun 30;21(1):164. doi: 10.1186/s12931-020-01432-x.
6
Pulmonary hypertension in chronic lung diseases.慢性肺部疾病相关肺动脉高压。
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16. doi: 10.1016/j.jacc.2013.10.036.
7
Respiratory mechanics measured by forced oscillation technique in combined pulmonary fibrosis and emphysema.运用强迫震荡技术测量肺纤维化合并肺气肿患者的呼吸力学。
Respir Physiol Neurobiol. 2013 Jan 15;185(2):235-40. doi: 10.1016/j.resp.2012.10.009. Epub 2012 Oct 29.
8
Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease.结缔组织病合并肺纤维化和肺气肿综合征
Arthritis Rheum. 2011 Jan;63(1):295-304. doi: 10.1002/art.30077.
9
Annual changes in pulmonary function in combined pulmonary fibrosis and emphysema: over a 5-year follow-up.特发性肺纤维化合并肺气肿患者的肺功能年度变化:5 年随访研究。
Respir Med. 2013 Dec;107(12):1986-92. doi: 10.1016/j.rmed.2013.06.015. Epub 2013 Jul 10.
10
Lung cancer in patients with combined pulmonary fibrosis and emphysema revisited with the 2015 World Health Organization classification of lung tumors.结合肺纤维化和肺气肿患者的肺癌:基于2015年世界卫生组织肺肿瘤分类的再探讨
Clin Respir J. 2018 Feb;12(2):652-658. doi: 10.1111/crj.12575. Epub 2016 Nov 3.

引用本文的文献

1
Advances and frontiers in pulmonary fibrosis and lung cancer research (2000-2024): a bibliometric analysis.肺纤维化与肺癌研究的进展与前沿(2000 - 2024):文献计量分析
Front Med (Lausanne). 2025 Jun 23;12:1596228. doi: 10.3389/fmed.2025.1596228. eCollection 2025.
2
The role of lung cancer in mortality rate in chronic fibrosing idiopathic interstitial pneumonia.肺癌在慢性纤维化性特发性间质性肺炎死亡率中的作用。
Sci Rep. 2025 May 14;15(1):16825. doi: 10.1038/s41598-025-99792-1.
3
Neutrophil-to-lymphocyte ratio as a prognostic marker for lung cancer in combined pulmonary fibrosis and emphysema patients.
中性粒细胞与淋巴细胞比值作为合并肺纤维化和肺气肿患者肺癌预后标志物的研究
Eur J Med Res. 2025 Apr 22;30(1):316. doi: 10.1186/s40001-025-02595-3.
4
Serum Krebs von den Lungen-6 as a potential biomarker for distinguishing combined pulmonary fibrosis and emphysema from chronic obstructive pulmonary disease: A retrospective study.血清肺表面活性蛋白A作为区分合并性肺纤维化和肺气肿与慢性阻塞性肺疾病的潜在生物标志物:一项回顾性研究
Heliyon. 2024 Jul 25;10(15):e35099. doi: 10.1016/j.heliyon.2024.e35099. eCollection 2024 Aug 15.
5
The effect of inhaler prescription on the development of lung cancer in COPD: a nationwide population-based study.吸入器处方对 COPD 患者肺癌发展的影响:一项基于全国人口的研究。
Respir Res. 2024 May 31;25(1):229. doi: 10.1186/s12931-024-02838-7.
6
Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision.特发性肺纤维化和进行性肺纤维化的治疗:2023 年澳大利亚和新西兰胸科学会立场声明的修订版。
Respirology. 2024 Feb;29(2):105-135. doi: 10.1111/resp.14656. Epub 2024 Jan 11.
7
Meta-analysis: clinical features and treatments of lung cancer in combined pulmonary fibrosis and emphysema.荟萃分析:合并肺纤维化和肺气肿的肺癌的临床特征与治疗
Sarcoidosis Vasc Diffuse Lung Dis. 2023 Dec 20;40(4):e2023045. doi: 10.36141/svdld.v40i4.14433.
8
Combined Pulmonary Fibrosis and Emphysema: Comparative Evidence on a Complex Condition.合并性肺纤维化和肺气肿:关于一种复杂病症的比较证据
Biomedicines. 2023 Jun 4;11(6):1636. doi: 10.3390/biomedicines11061636.
9
Combined Pulmonary Fibrosis and Emphysema: When Scylla and Charybdis Ally.肺纤维化合并肺气肿:当斯库拉和卡律布狄斯结盟。
Cells. 2023 Apr 28;12(9):1278. doi: 10.3390/cells12091278.
10
Lung Imaging in COPD Part 1: Clinical Usefulness.COPD 的肺部影像学表现(一):临床应用价值。
Chest. 2023 Jul;164(1):69-84. doi: 10.1016/j.chest.2023.03.007. Epub 2023 Mar 11.